Meropenem Hikma (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious infections affecting various organ systems.

• Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal sepsis.
• Complicated urinary tract infections: provides rapid bacterial clearance and symptom resolution.
• Hospital‑acquired pneumonia: improves lung infection outcomes in ventilated patients.
• Septicemia: offers broad coverage against Gram‑negative and Gram‑positive pathogens in bloodstream infections.
• Skin and soft tissue infections: facilitates healing by eliminating resistant bacterial strains.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its broad spectrum includes many Gram‑negative, Gram‑positive, and anaerobic organisms, making it effective for severe nosocomial infections.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in many patients.
• Diarrhea: loose stools that may be self‑limiting.
• Rash: skin erythema or pruritus.
• Infusion site phlebitis: pain or redness at the IV site.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or high doses.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Anaphylaxis: acute allergic reaction requiring immediate medical attention.
• Severe neutropenia: marked reduction in white blood cells.
• Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

• Renal function: adjust dose in patients with impaired clearance.
• Hypersensitivity: avoid in individuals with known carbapenem or beta‑lactam allergy.
• Pregnancy: category B; use only when benefits outweigh potential risks.
• Concomitant valproic acid: monitor for reduced antiepileptic levels.
• Monitoring: observe for neurologic changes, especially seizures, during high‑dose therapy.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Meropenem can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Valproic acid: meropenem markedly reduces serum valproate concentrations, risking seizure breakthrough.
• Probenecid: may increase meropenem plasma levels, heightening toxicity.
• High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely)

• Loop diuretics: electrolyte shifts may predispose to seizures.
• Other nephrotoxic agents (e.g., vancomycin): monitor renal function.
• Oral contraceptives: possible reduction in contraceptive effectiveness; advise alternative birth control.